drugset
Drugs / Retagliptin
last change May 2026 re-read 9 days ago

Retagliptin

also known as SP2086 · Retagliptin phosphate

Small molecule

Developed for
type 2 diabetes mellitus
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Shandong Suncadia Medicine Co., Ltd. · Peking University First Hospital

Trials 18

today NCT06417489 · Ph 4 NCT06035406 · Ph 1 NCT05692934 · Ph 1 NCT05682495 · Ph 1 NCT05054842 · Ph 3 NCT04667143 · Ph 3 NCT02826044 · Ph 1 NCT02822534 · Ph 1 NCT02817217 · Ph 1 NCT02817243 · Ph 1 NCT02821871 · Ph 1 NCT02813863 · Ph 1 NCT02815748 · Ph 1 NCT02500485 · Ph 1 NCT01970046 · Ph 3 NCT01970033 · Ph 3 NCT01969318 · Ph 2 NCT01969357 · Ph 2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 111 trials
Phase 1 NCT06035406 Sep → Dec 2023 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT05692934 Jan → Mar 2023 type 2 diabetes mellitus Shandong Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05682495 Jan → Apr 2023 type 2 diabetes mellitus Shandong Suncadia Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT02826044 Jul → Sep 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02822534 Apr → Jul 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02817217 Mar → Jul 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02817243 Mar → Jul 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02821871 Mar → Sep 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02813863 Dec 2015 → Mar 2016 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT02815748 Aug → Oct 2015 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01969318 Mar → Aug 2012 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 2 NCT01969357 Jun 2011 → Apr 2012 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 34 trials
Phase 3 NCT05054842 Dec 2021 → Dec 2023 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 3 NCT04667143 Jan 2021 → Sep 2022 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 3 NCT01970046 Apr 2013 → Jan 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 3 NCT01970033 Dec 2012 → Jan 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT06417489 May 2024 → May 2026 overdue type 2 diabetes mellitus Peking University First Hospital Not yet recruiting No outcome recorded
Comparator or background therapy4 trials
Phase 1 NCT02815774 Comparator Jun 2014 → Jan 2015 impaired renal function disease Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT02815787 Comparator Mar → Jul 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT02815722 Comparator Jul 2013 → May 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT02815657 Comparator Apr 2013 → Jan 2014 type 2 diabetes mellitus Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 23 sources stand behind the page.

FieldValueCited text
Known as Retagliptin “Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients” NCT06417489 ↗
3

NCT04667143 ↗

NCT05054842 ↗

NCT06035406 ↗
Known as Retagliptin phosphate “Retagliptin phosphate tablet is a DPP IV inhibitor durg” NCT05054842 ↗
Known as SP2086 “The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.” NCT05692934 ↗
17

“Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout” NCT05682495 ↗

NCT02815774 ↗

NCT02817217 ↗

NCT02815787 ↗

NCT02826044 ↗

NCT02821871 ↗

NCT02822534 ↗

NCT01970046 ↗

NCT01970033 ↗

NCT02813863 ↗

Show 7 more sources
Action Inhibit “SP2086 is a new dipeptidyl peptidase(DPP)-4 inhibitor.” NCT01969318 ↗
Modality Small molecule — CHEMBL4297435 ↗
Route Oral “SP2086 will be administered orally (by mouth) as 100mg” NCT02500485 ↗